北米の薬物送達デバイス市場 - 業界動向と2029年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

北米の薬物送達デバイス市場 - 業界動向と2029年までの予測

  • Medical Devices
  • Upcoming Report
  • Aug 2024
  • North America
  • 175 ページ
  • テーブル数: 170
  • 図の数: 29

北米の薬物送達デバイス市場

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
2024 –2031
Diagram 市場規模(基準年)
USD 788.49 Billion
Diagram Market Size (Forecast Year)
USD 1,351.11 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Panacea Biotec Ltd
  • AptarGroup
  • Koninklijke Philips N.V.
  • Nemera
  • Biocorp Production

>北米の薬物送達デバイス市場、投与経路別(経口薬物送達、注射薬物送達、局所薬物送達、眼薬物送達、肺薬物送達、経鼻薬物送達、経粘膜薬物送達および埋め込み型薬物送達)、患者ケア環境別(病院、診断センター、外来手術センター/クリニック、在宅ケア環境など)、用途別(がん、感染症、呼吸器疾患、糖尿病、心血管疾患、自己免疫疾患、中枢神経系疾患など)、国別(米国、カナダ、メキシコ)業界動向および2029年までの予測

北米の薬物送達デバイス市場市場分析と洞察:北米の薬物送達デバイス市場

薬物送達デバイス市場は、2022年から2029年の予測期間に7.29%の市場成長率を示すことが予想されています。薬物送達デバイス市場に関するデータブリッジ市場調査レポートは、予測期間を通じて普及すると予想されるさまざまな要因に関する分析と洞察を提供し、市場の成長への影響を示しています。医療インフラの開発に対する支出の増加は、薬物送達デバイス市場の成長を加速させています。

名前からわかるように、薬物送達装置は、投与量を効率的に標的部位に送達するために使用される医療機器です。薬物送達装置は、治療に関する患者の問題を特定し、病気の正確な場所に薬物を投与するのに役立ちます。

予測期間中に薬物送達デバイス市場の成長を後押しすると予想される主な要因は、世界中で骨粗鬆症、がん、呼吸器疾患、糖尿病、心血管疾患の罹患率が高まっていることです。さらに、医療インフラの開発に対する支出の増加、高齢者人口の増加、ハイテク開発と新製品の発売が、薬物送達デバイス市場の成長をさらに促進すると予想されます。一方、副作用や傷害のリスク、大手メーカーのデバイスのさまざまな製品リコールは、タイムライン期間中の薬物送達デバイス市場の成長をさらに妨げると予測されています。

さらに、満たされていない医療ニーズの高まりにより、医療サービスと個人の可処分所得に対する需要が増大し、今後数年間で薬物送達デバイス市場の成長にさらなる機会がもたらされるでしょう。ただし、発展途上国および低開発国における不利な償還シナリオにより、近い将来、薬物送達デバイス市場の成長にさらなる課題が生じる可能性があります。

この薬物送達デバイス市場レポートは、最近の新しい開発、貿易規制、輸出入分析、生産分析、バリュー チェーンの最適化、市場シェア、国内および現地の市場プレーヤーの影響、新たな収益源の観点から見た機会の分析、市場規制の変更、戦略的市場成長分析、市場規模、カテゴリ市場の成長、アプリケーションのニッチと優位性、製品の承認、製品の発売、地理的拡張、市場における技術革新の詳細を提供します。薬物送達デバイス市場の詳細については、アナリスト ブリーフについて Data Bridge Market Research にお問い合わせください。当社のチームが、市場の成長を達成するための情報に基づいた市場決定を行うお手伝いをします。

北米の薬物送達デバイス市場の範囲と市場規模

薬物送達デバイス市場は、投与経路、患者ケア環境、および用途に基づいてセグメント化されています。これらのセグメントの成長は、業界におけるわずかな成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供し、コア市場アプリケーションの特定に関する戦略的決定に役立ちます。

  • 投与経路に基づいて、薬物送達デバイス市場は、経口薬物送達、注射薬物送達、局所薬物送達、眼薬物送達、肺薬物送達、鼻薬物送達、経粘膜薬物送達、および埋め込み型薬物送達に分類されます。
  • 患者ケア環境に基づいて、薬物送達デバイス市場は、病院、診断センター、外来手術センターまたはクリニック、在宅ケア環境などに分類されます。
  • 用途に基づいて、薬物送達デバイス市場は、がん、感染症、呼吸器疾患、糖尿病、心血管疾患、自己免疫疾患、中枢神経系障害などに分類されます。

薬物送達デバイス市場の国別分析

薬物送達デバイス市場が分析され、市場規模の洞察と傾向が、上記のように国、投与経路、患者ケア環境、およびアプリケーション別に提供されます。

薬物送達デバイス市場レポートで取り上げられている国は、北米では米国、カナダ、メキシコです。

薬物送達デバイス市場レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。消費量、生産拠点と量、輸出入分析、価格動向分析、原材料費、下流および上流のバリューチェーン分析などのデータポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、グローバルブランドの存在と入手可能性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。

患者疫学分析

薬物送達デバイス市場では、患者分析、予後、治療法に関する詳細な市場分析も提供されます。有病率、発症率、死亡率、遵守率は、レポートで利用できるデータ変数の一部です。疫学が薬物送達デバイス市場の成長に直接的または間接的に与える影響を分析し、成長期の薬物送達デバイス市場を予測するためのより堅牢なコホート多変量統計モデルを作成します。

競争環境と薬物送達デバイスの市場シェア分析

薬物送達デバイス市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、生み出される収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、薬物送達デバイス市場に関連する会社の焦点にのみ関連しています。

薬物送達デバイス市場レポートで活動している主要企業には、Panacea Biotec Ltd、AptarGroup, Inc、Koninklijke Philips NV、Nemera、Biocorp Production、Valeritas Holdings Inc.、Ethicon、Eli Lilly and Company、Accord Healthcare Ltd.、BD、Bayer AG、Johnson & Johnson Services, Inc.、Novartis AG、Pfizer, Inc.、F. Hoffmann-La Roche AG、GlaxoSmithKline plc.、Merck & Co.、Sanofi、3M などがあります。


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

目次

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USER COVERAGE GRID

2.8 PRODUCT TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTERS FIVE FORCES

4.2 PESTEL ANALYSIS

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE

6.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS DRUGS DEVICES

6.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT

6.1.4 INCREASED FOCUS ON PERSONALIZED MEDICINE AND DEVICES

6.2 RESTRAINTS

6.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS

6.2.2 HIGH COSTS OF INJECTABLE DRUGS

6.2.3 STRINGENT REGULATORY SCENARIO

6.3 OPPORTUNITIES

6.3.1 RISING ACCEPTANCE OF SELF-ADMINISTERING DRUG DEVICES

6.3.2 RISING DEMAND FOR BIOSIMILAR AND GENERIC DRUGS

6.3.3 THERAPEUTIC ADVANCEMENTS IN THE FIELD OF DRUG DELIVERY

6.4 CHALLENGES

6.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS

6.4.2 INCREASE IN THE NUMBER OF ALTERNATIVES OF DRUG DELIVERY

7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 ORAL DRUG DELIVERY

7.2.1 SOLID ORAL DRUGS

7.2.1.1 TABLETS

7.2.1.2 CAPSULES

7.2.1.3 PILLS

7.2.1.4 POWDERS

7.2.2 LIQUID ORAL DRUGS

7.2.2.1 SYRUPS

7.2.2.2 SOLUTIONS

7.2.3 SEMI SOLID ORAL DRUGS

7.2.3.1 GELS

7.2.3.2 EMULSIONS

7.2.3.3 ELIXIRS

7.3 INJECTABLE DRUG DELIVERY

7.3.1 INJECTABLE DRUG DELIVERY FORMULATIONS

7.3.1.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS

7.3.1.2 NOVEL DRUG DELIVERY FORMULATIONS

7.3.1.3 LONG ACTING INJECTION FORMULATIONS

7.3.2 INJECTABLE DRUG DELIVERY DEVICES

7.3.2.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES

7.3.2.1.1 BY MATERIAL

7.3.2.1.1.1 GLASS

7.3.2.1.1.2 PLASTIC

7.3.2.1.2 BY PRODUCT TYPE

7.3.2.1.2.1 FILLABLE

7.3.2.1.2.2 PRE-FILLED

7.3.2.1.3 BY USABILITY

7.3.2.1.3.1 REUSABLE SYRINGES

7.3.2.1.3.2 DISPOSABLE SYRINGES

7.3.2.2 SELF INJECTION DRUG DELIVERY DEVICES

7.3.2.2.1 NEEDLE FREE INJECTORS

7.3.2.2.2 WEARABLE INJECTORS

7.3.2.2.3 PEN INJECTOR

7.3.2.2.4 AUTO INJECTORS

7.3.2.2.5 OTHERS

7.4 TOPICAL DRUG DELIVERY

7.4.1 TRANSDERMAL DRUG DELIVERY FORMULATIONS

7.4.1.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS

7.4.1.1.1 OINTMENTS

7.4.1.1.2 CREAMS

7.4.1.1.3 LOTIONS

7.4.1.1.4 GELS

7.4.1.1.5 PASTES

7.4.1.2 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS

7.4.1.2.1 SUSPENSIONS

7.4.1.2.2 SOLUTIONS

7.4.1.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS

7.4.1.3.1 POWDER

7.4.1.3.2 SUPPOSITORS

7.5 OPHTHALMIC DRUG DELIVERY

7.5.1 OCCULAR DRUG DELIVERY FORMULATIONS

7.5.1.1 LIQUID OCCULAR DRUG DELIVERY FORMULATIONS

7.5.1.1.1 SOLUTIONS

7.5.1.1.2 SUSPENSIONS

7.5.1.2 SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS

7.5.1.2.1 GELS

7.5.1.2.2 OINTMENTS

7.5.2 OCCULAR DRUG DELIVERY DEVICES

7.6 NASAL DRUG DELIVERY

7.6.1 NASAL DROPS

7.6.2 NASAL SPRAYS

7.6.3 NASAL POWDERS

7.6.4 NASAL GELS

7.7 PULMONARY DRUG DELIVERY

7.7.1 METERED DOSE INHALERS (MDI)

7.7.2 DRY POWDER INHALERS (DPI)

7.7.3 NEBULIZERS

7.7.3.1 JET NEBULIZERS

7.7.3.2 ULTRASONIC NEBULIZERS

7.7.3.3 SOFT MIST NEBULIZERS

7.8 TRANSMUCOSAL DRUG DELIVERY

7.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY

7.8.1.1 BUCCAL DRUG DELIVERY

7.8.1.2 SUBLINGUAL DRUG DELIVERY

7.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY

7.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY

7.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY

7.9 IMPLANTABLE DRUG DELIVERY

7.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES

7.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES

8 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS

8.3 HOME HEALTHCARE

8.4 CLINICS

8.5 COMMUNITY HEALTHCARE

8.6 OTHERS

9 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 DIRECT TENDERS

9.3 HOSPITAL PHARMACIES

9.4 PHARMACY STORES

9.5 ONLINE PHARMACY

10 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY REGION

10.1 NORTH AMERICA

10.1.1 U.S.

10.1.2 CANADA

10.1.3 MEXICO

11 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY LANDSCAPE

11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

12 SWOT ANALYSIS

13 COMPANY PROFILE

13.1 JOHNSON & JOHNSON SERVICES, INC.

13.1.1 COMPANY SNAPSHOT

13.1.2 REVENUE ANALYSIS

13.1.3 COMPANY SHARE ANALYSIS

13.1.4 PRODUCT PORTFOLIO

13.1.5 RECENT DEVELOPMENTS

13.2 NOVARTIS AG

13.2.1 COMPANY SNAPSHOT

13.2.2 REVENUE ANALYSIS

13.2.3 COMPANY SHARE ANALYSIS

13.2.4 PRODUCT PORTFOLIO

13.2.5 RECENT DEVELOPMENTS

13.3 F. HOFFMANN-LA ROCHE LTD

13.3.1 COMPANY SNAPSHOT

13.3.2 REVENUE ANALYSIS

13.3.3 COMPANY SHARE ANALYSIS

13.3.4 PRODUCT PORTFOLIO

13.3.5 RECENT DEVELOPMENT

13.4 BAYER AG

13.4.1 COMPANY SNAPSHOT

13.4.2 REVENUE ANALYSIS

13.4.3 COMPANY SHARE ANALYSIS

13.4.4 PRODUCT PORTFOLIO

13.5 PFIZER INC.

13.5.1 COMPANY SNAPSHOT

13.5.2 REVENUE ANALYSIS

13.5.3 COMPANY SHARE ANALYSIS

13.5.4 PRODUCT PORTFOLIO

13.5.5 RECENT DEVELOPMENT

13.6 3M

13.6.1 COMPANY SNAPSHOT

13.6.2 REVENUE ANALYSIS

13.6.3 PRODUCT PORTFOLIO

13.6.4 RECENT DEVELOPMENTS

13.7 ABBVIE INC.

13.7.1 COMPANY SNAPSHOT

13.7.2 REVENUE ANALYSIS

13.7.3 PRODUCT PORTFOLIO

13.7.4 RECENT DEVELOPMENTS

13.8 AMGEN INC.

13.8.1 COMPANY SNAPSHOT

13.8.2 REVENUE ANALYSIS

13.8.3 PRODUCT PORTFOLIO

13.8.4 RECENT DEVELOPMENTS

13.9 BD

13.9.1 COMPANY SNAPSHOT

13.9.2 REVENUE ANALYSIS

13.9.3 PRODUCT PORTFOLIO

13.9.4 RECENT DEVELOPMENT

13.1 ELCAM MEDICAL

13.10.1 COMPANY SNAPSHOT

13.10.2 PRODUCT PORTFOLIO

13.10.3 RECENT DEVELOPMENT

13.11 ENABLE INJECTIONS

13.11.1 COMPANY SNAPSHOT

13.11.2 PRODUCT PORTFOLIO

13.11.3 RECENT DEVELOPMENTS

13.12 GERRESHEIMER AG

13.12.1 COMPANY SNAPSHOT

13.12.2 REVENUE ANALYSIS

13.12.3 PRODUCT PORTFOLIO

13.12.4 RECENT DEVELOPMENTS

13.13 GSK PLC.

13.13.1 COMPANY SNAPSHOT

13.13.2 REVENUE ANALYSIS

13.13.3 PRODUCT PORTFOLIO

13.13.4 RECENT DEVELOPMENTS

13.14 INSULET CORPORATION

13.14.1 COMPANY SNAPSHOT

13.14.2 REVENUE ANALYSIS

13.14.3 PRODUCT PORTFOLIO

13.14.4 RECENT DEVELOPMENTS

13.15 MEDMIX

13.15.1 COMPANY SNAPSHOT

13.15.2 REVENUE ANALYSIS

13.15.3 PRODUCT PORTFOLIO

13.15.4 RECENT DEVELOPMENTS

13.16 MERCK & CO., INC.

13.16.1 COMPANY SNAPSHOT

13.16.2 REVENUE ANALYSIS

13.16.3 PRODUCT PORTFOLIO

13.16.4 RECENT DEVELOPMENT

13.17 ORASURE TECHNOLOGIES INC.

13.17.1 COMPANY SNAPSHOT

13.17.2 REVENUE ANALYSIS

13.17.3 PRODUCT PORTFOLIO

13.17.4 RECENT DEVELOPMENT

13.18 SANOFI

13.18.1 COMPANY SNAPSHOT

13.18.2 REVENUE ANALYSIS

13.18.3 PRODUCT PORTFOLIO

13.18.4 RECENT DEVELOPMENTS

13.19 SMC LTD.

13.19.1 COMPANY SNAPSHOT

13.19.2 REVENUE ANALYSIS

13.19.3 PRODUCT PORTFOLIO

13.19.4 RECENT DEVELOPMENTS

13.2 VIVO SMART MEDICAL DEVICES LTD.

13.20.1 COMPANY SNAPSHOT

13.20.2 PRODUCT PORTFOLIO

13.20.3 RECENT DEVELOPMENT

13.21 WEST PHARMACEUTICAL SERVICES, INC.

13.21.1 COMPANY SNAPSHOT

13.21.2 REVENUE ANALYSIS

13.21.3 PRODUCT PORTFOLIO

13.21.4 RECENT DEVELOPMENT

14 QUESTIONNAIRE

15 RELATED REPORTS

表のリスト

TABLE 1 LIST OF FDA APPROVED BIOLOGICS, IN 2022

TABLE 2 10 MOST EXPENSIVE DRUGS IN THE U.S. (IN USD MILLION)

TABLE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 4 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 5 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 6 NORTH AMERICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 7 NORTH AMERICA LIQUID ORAL DRUG IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 8 NORTH AMERICA SEMI SOLID ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 9 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 10 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 11 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 12 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 13 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)

TABLE 14 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE 2022-2031 (USD MILLION)

TABLE 15 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 16 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 17 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 18 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 19 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 20 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 21 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 22 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 23 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 24 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 25 NORTH AMERICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 26 NORTH AMERICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 27 NORTH AMERICA SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 28 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 29 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 30 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 31 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 32 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 33 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 34 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 35 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 36 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 37 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 38 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 39 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 40 NORTH AMERICA HOSPITALS IN DRUG DELIVERY MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 41 NORTH AMERICA HOME HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 42 NORTH AMERICA CLINICS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 43 NORTH AMERICA COMMUNITY HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 44 NORTH AMERICA OTHERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 45 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 46 NORTH AMERICA DIRECT TENDERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 47 NORTH AMERICA HOSPITAL PHARMACIES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 48 NORTH AMERICA PHARMACY STORES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 49 NORTH AMERICA ONLINE PHARMACY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 50 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 51 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 52 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 53 NORTH AMERICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 54 NORTH AMERICA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 55 NORTH AMERICA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 56 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 57 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 58 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 59 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)

TABLE 60 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 61 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 62 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 63 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 64 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 65 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 66 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 67 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 68 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 69 NORTH AMERICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 70 NORTH AMERICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 71 NORTH AMERICA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 72 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 73 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 74 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 75 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 76 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 77 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 78 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 79 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 80 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 81 U.S. DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 82 U.S. ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 83 U.S. SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 84 U.S. LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 85 U.S. SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 86 U.S. INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 87 U.S. INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 88 U.S. INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 89 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)

TABLE 90 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 91 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 92 U.S. SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 93 U.S. TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 94 U.S. TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 95 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 96 U.S. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 97 U.S. SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 98 U.S. OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 99 U.S. OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 100 U.S. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 101 U.S. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 102 U.S. NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 103 U.S. PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 104 U.S. NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 105 U.S. TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 106 U.S. ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 107 U.S. OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 108 U.S. IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 109 U.S. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 110 U.S. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 111 CANADA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 112 CANADA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 113 CANADA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 114 CANADA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 115 CANADA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 116 CANADA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 117 CANADA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 118 CANADA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 119 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)

TABLE 120 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 121 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 122 CANADA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 123 CANADA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 124 CANADA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 125 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 126 CANADA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 127 CANADA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 128 CANADA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 129 CANADA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 130 CANADA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 131 CANADA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 132 CANADA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 133 CANADA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 134 CANADA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 135 CANADA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 136 CANADA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 137 CANADA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 138 CANADA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 139 CANADA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 140 CANADA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 141 MEXICO DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 142 MEXICO ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 143 MEXICO SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 144 MEXICO LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 145 MEXICO SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 146 MEXICO INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 147 MEXICO INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 148 MEXICO INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 149 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)

TABLE 150 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 151 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 152 MEXICO SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)

TABLE 153 MEXICO TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 154 MEXICO TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 155 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 156 MEXICO LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 157 MEXICO SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 158 MEXICO OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 159 MEXICO OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)

TABLE 160 MEXICO LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 161 MEXICO SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 162 MEXICO NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 163 MEXICO PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 164 MEXICO NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 165 MEXICO TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 166 MEXICO ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 167 MEXICO OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 168 MEXICO IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 169 MEXICO DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 170 MEXICO DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)

図表一覧

FIGURE 1 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION

FIGURE 11 EXECUTIVE SUMMARY

FIGURE 12 EIGHT SEGMENTS COMPRISE THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

FIGURE 13 STRATEGIC DECISIONS

FIGURE 14 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE ARE DRIVING THE GROWTH OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET FROM 2024 TO 2031

FIGURE 15 THE ORAL DRUG DELIVERY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET IN 2024 AND 2031

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA DRUG DELIVERY DEVICES MARKET

FIGURE 17 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023

FIGURE 18 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023-2031 (USD MILLION)

FIGURE 19 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, CAGR (2024-2031)

FIGURE 20 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 21 NORTH AMERICA DRUG DELIVERY MARKET: BY END USER, 2023

FIGURE 22 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY END USER, 2024-2031 (USD MILLION)

FIGURE 23 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: END USER, CAGR (2024-2031)

FIGURE 24 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: END USER, LIFELINE CURVE

FIGURE 25 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 26 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 27 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 28 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 29 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE 2023 (%)

詳細情報を見る Right Arrow

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The market is segmented based on , By Product Type (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug Delivery, Pulmonary Drug Delivery, Transmucosal Drug Delivery, and Implantable Drug Delivery), End User (Hospitals, Home Healthcare, Clinics, Community Healthcare and Others), Distribution Channel (Direct Tenders, Hospital Pharmacies, Pharmacy Stores, and Online Pharmacy) - Industry Trends and Forecast to 2031. .
The North America Drug Delivery Devices Market size was valued at USD 788.49 USD Billion in 2023.
The North America Drug Delivery Devices Market is projected to grow at a CAGR of 7.3% during the forecast period of 2024 to 2031.
The major players operating in the market include Panacea Biotec Ltd, AptarGroup , Koninklijke Philips N.V., Nemera, Biocorp Production, Valeritas Holdings , Ethicon, Eli Lilly and Company, Accord Healthcare , BD, Bayer AG, Johnson & Johnson Services , Novartis AG, Pfizer , F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck & Co., Sanofi, and 3M .
The market report covers data from the U.S., Canada, and Mexico.